首页 > 最新文献

Medicinal Chemistry最新文献

英文 中文
Synthesis and Antiproliferative Activity Evaluation of B-norcholesterol-6- amide Compounds. b -去甲胆固醇-6-酰胺类化合物的合成及抗增殖活性评价。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666230117101950
Yanmin Huang, Zining Peng, Chang Liu, Chunling Pang, Sijing Chen, Chunfang Gan, Zhiping Liu, Jianguo Cui

Background: The structure modification of steroids is commonly used to change the biological activity of steroids in medicinal chemistry. In recent years, it has been found that some derivatives derived from the structural modification of cholesterol display good inhibitory activity against tumor cell proliferation in vitro.

Methods: Using cholesterol as the starting material, different types of B-norcholesterol-6-amide derivatives were synthesized by the reaction of 6-carboxyl-B-norcholesterol with different alkyl amines or 6-amino-B-norcholesterol with different acyl chlorides. The inhibitory activity of compounds on the proliferation of tumor cell lines was investigated by the MTT method.

Results: The results showed that the B-norcholesterol-6-amide compounds displayed distinct cytotoxicity against Sk-Ov-3 cells but caused no obvious damage against HEK-293T cells. Additionally, the steroidal amide derivatives formed from 6-amino-B-norcholesterol showed stronger cytotoxicity than those produced from 6-carboxyl-B-norcholesterol. Specially, compounds with chloroalkyl structure displayed significant inhibitory activity against all tumor cells tested. Among them, compounds 19-21 showed cytotoxicity like 2-methoxyestradiol as a positive control, and the IC50 value of compound 20 on HeLa cells was 3.9 μM.

Conclusion: After introducing chloroalkyl acyl groups into 6-position of 6-amino-B-norcholesterol, the cytotoxicity of resulting B-norcholesterol-6-amide compounds can be greatly enhanced.

背景:类固醇的结构修饰是药物化学中常用的改变类固醇生物活性的方法。近年来,人们发现一些由胆固醇结构修饰衍生的衍生物在体外对肿瘤细胞增殖表现出良好的抑制活性。方法:以胆固醇为原料,通过6-羧基- b -去胆固醇与不同的烷基胺或6-氨基- b -去胆固醇与不同的酰基氯化物反应合成不同类型的b -去胆固醇-6-酰胺衍生物。用MTT法研究了化合物对肿瘤细胞增殖的抑制作用。结果:b -去甲胆固醇-6-酰胺化合物对Sk-Ov-3细胞具有明显的细胞毒性,对HEK-293T细胞无明显损伤。此外,6-氨基- b -去胆固醇生成的甾体酰胺衍生物比6-羧基- b -去胆固醇生成的甾体酰胺衍生物具有更强的细胞毒性。特别地,含有氯烷基结构的化合物对所有肿瘤细胞都有明显的抑制活性。其中化合物19-21与阳性对照2-甲氧基雌二醇一样具有细胞毒性,化合物20对HeLa细胞的IC50值为3.9 μM。结论:在6-氨基- b -去甲胆固醇的6位引入氯烷基酰基后,所得到的b -去甲胆固醇-6-酰胺化合物的细胞毒性可显著增强。
{"title":"Synthesis and Antiproliferative Activity Evaluation of B-norcholesterol-6- amide Compounds.","authors":"Yanmin Huang,&nbsp;Zining Peng,&nbsp;Chang Liu,&nbsp;Chunling Pang,&nbsp;Sijing Chen,&nbsp;Chunfang Gan,&nbsp;Zhiping Liu,&nbsp;Jianguo Cui","doi":"10.2174/1573406419666230117101950","DOIUrl":"https://doi.org/10.2174/1573406419666230117101950","url":null,"abstract":"<p><strong>Background: </strong>The structure modification of steroids is commonly used to change the biological activity of steroids in medicinal chemistry. In recent years, it has been found that some derivatives derived from the structural modification of cholesterol display good inhibitory activity against tumor cell proliferation in vitro</i>.</p><p><strong>Methods: </strong>Using cholesterol as the starting material, different types of B-norcholesterol-6-amide derivatives were synthesized by the reaction of 6-carboxyl-B-norcholesterol with different alkyl amines or 6-amino-B-norcholesterol with different acyl chlorides. The inhibitory activity of compounds on the proliferation of tumor cell lines was investigated by the MTT method.</p><p><strong>Results: </strong>The results showed that the B-norcholesterol-6-amide compounds displayed distinct cytotoxicity against Sk-Ov-3 cells but caused no obvious damage against HEK-293T cells. Additionally, the steroidal amide derivatives formed from 6-amino-B-norcholesterol showed stronger cytotoxicity than those produced from 6-carboxyl-B-norcholesterol. Specially, compounds with chloroalkyl structure displayed significant inhibitory activity against all tumor cells tested. Among them, compounds 19-21 showed cytotoxicity like 2-methoxyestradiol as a positive control, and the IC</i><sub>50</sub> value of compound 20 on HeLa cells was 3.9 μM.</p><p><strong>Conclusion: </strong>After introducing chloroalkyl acyl groups into 6-position of 6-amino-B-norcholesterol, the cytotoxicity of resulting B-norcholesterol-6-amide compounds can be greatly enhanced.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9527709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Insight into COVID-19 and Traditional Herbs: Bangladesh Perspective. 透视COVID-19和传统草药:孟加拉国视角。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406418666220829144746
Md Mominur Rahman, Sheikh Shohag, Md Rezaul Islam, Shomaya Akhter, Sadia Afsana Mim, Rohit Sharma, Abdur Rauf

SARS-CoV-2 was first discovered in Wuhan in late 2019 and has since spread over the world, resulting in the present epidemic. Because targeted therapeutics are unavailable, scientists have the opportunity to discover new drugs or vaccines to counter COVID-19, and therefore a number of synthetic bioactive compounds are now being tested in clinical studies. Due to its broad therapeutic spectrum and low adverse effects, medicinal herbs have been used as traditional healing medication in those countries for ages. Due to a lack of synthetic bioactive antiviral medications, pharmaceutical and alternative therapies have been developed using a variety of herbal compositions. Due to the widespread availability of herbal and dietary products worldwide, people frequently use them. Notably, the majority of Bangladeshi people continue to use a variety of natural plants and herbs to treat various types of diseases. This review article discusses how previous research has shown that some herbs in Bangladesh have immunomodulatory and antiviral effects and how their active ingredients have been gathered. Even though FDA-approved medications and vaccines are available for the treatment of COVID-19, the purpose is to encourage the use of herbal medicine as immunomodulators and vaccine adjuvants for the treatment of COVID-19 prevention.

SARS-CoV-2于2019年底在武汉首次被发现,此后蔓延到世界各地,导致了目前的疫情。由于没有靶向治疗方法,科学家有机会发现新的药物或疫苗来对抗COVID-19,因此许多合成生物活性化合物正在临床研究中进行测试。由于其广泛的治疗范围和低副作用,草药在这些国家被用作传统的治疗药物已有很长时间了。由于缺乏合成的生物活性抗病毒药物,已经开发了使用各种草药组合物的药物和替代疗法。由于草药和膳食产品在世界范围内的广泛可用性,人们经常使用它们。值得注意的是,大多数孟加拉国人继续使用各种天然植物和草药来治疗各种疾病。这篇综述文章讨论了先前的研究如何表明孟加拉国的一些草药具有免疫调节和抗病毒作用,以及如何收集它们的有效成分。尽管fda批准的药物和疫苗可用于治疗COVID-19,但其目的是鼓励使用草药作为免疫调节剂和疫苗佐剂来预防COVID-19的治疗。
{"title":"An Insight into COVID-19 and Traditional Herbs: Bangladesh Perspective.","authors":"Md Mominur Rahman,&nbsp;Sheikh Shohag,&nbsp;Md Rezaul Islam,&nbsp;Shomaya Akhter,&nbsp;Sadia Afsana Mim,&nbsp;Rohit Sharma,&nbsp;Abdur Rauf","doi":"10.2174/1573406418666220829144746","DOIUrl":"https://doi.org/10.2174/1573406418666220829144746","url":null,"abstract":"<p><p>SARS-CoV-2 was first discovered in Wuhan in late 2019 and has since spread over the world, resulting in the present epidemic. Because targeted therapeutics are unavailable, scientists have the opportunity to discover new drugs or vaccines to counter COVID-19, and therefore a number of synthetic bioactive compounds are now being tested in clinical studies. Due to its broad therapeutic spectrum and low adverse effects, medicinal herbs have been used as traditional healing medication in those countries for ages. Due to a lack of synthetic bioactive antiviral medications, pharmaceutical and alternative therapies have been developed using a variety of herbal compositions. Due to the widespread availability of herbal and dietary products worldwide, people frequently use them. Notably, the majority of Bangladeshi people continue to use a variety of natural plants and herbs to treat various types of diseases. This review article discusses how previous research has shown that some herbs in Bangladesh have immunomodulatory and antiviral effects and how their active ingredients have been gathered. Even though FDA-approved medications and vaccines are available for the treatment of COVID-19, the purpose is to encourage the use of herbal medicine as immunomodulators and vaccine adjuvants for the treatment of COVID-19 prevention.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9540539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Identification of Non-steroidal Aromatase Inhibitors via In silico and In vitro Studies 通过硅学和体外研究鉴定非甾体类芳香化酶抑制剂
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666230330082426
Humaira Zafar, Rabbia Anis, Sana Hafeez, Atia-Tul Wahab, Maria Aqeel Khan, Fatima Zehra Basha, Innokentiy Maslennikov, Muhammad Iqbal Choudhary

Introduction: Breast cancer is the most common cancer affecting women worldwide,including Pakistan. More than half of breast cancer patients have hormone-dependent breast cancer,which is developed due to the over-production of estrogen (the main hormone in breast cancer).

Method: The biosynthesis of estrogen is catalyzed by the aromatase enzyme, which thus serves as atarget for the treatment of breast cancer. During the current study, biochemical, computational, andSTD-NMR methods were employed to identify new aromatase inhibitors. A series of phenyl-3-butene-2-one derivatives 1-9 were synthesized and evaluated for human placental aromatase inhibitory activity. Among them, four compounds 2, 3, 4, and 8 showed a moderate to weak inhibitory activity (IC50 = 22.6 - 47.9 µM), as compared to standard aromatase inhibitory drugs, letrozole (IC50 =0.0147 ± 1.45 µM), anastrozole (IC50 = 0.0094 ± 0.91 µM), and exemestane (IC50 = 0.2 ± 0.032 µM).Kinetic studies on two moderate inhibitors, 4 and 8, revealed a competitive- and mixed-type of inhibition, respectively.

Result: Docking studies on all active compounds indicated their binding adjacent to the heme groupand interaction with Met374, a critical residue of aromatase. STD-NMR further highlighted the interactions of these ligands with the aromatase enzyme.

Conclusion: STD-NMR-based epitope mapping indicated close proximity of the alkyl chain followed by an aromatic ring with the receptor (aromatase). These compounds were also found to benon-cytotoxic against human fibroblast cells (BJ cells). Thus, the current study has identified newaromatase inhibitors (compounds 4, and 8) for further pre-clinical and clinical research.

导言乳腺癌是包括巴基斯坦在内的全世界妇女最常见的癌症。一半以上的乳腺癌患者是激素依赖型乳腺癌,其发病原因是雌激素(乳腺癌的主要激素)分泌过多:方法:雌激素的生物合成是由芳香化酶催化的,因此芳香化酶是治疗乳腺癌的靶点。本研究采用生化、计算和 STD-NMR 方法鉴定新的芳香化酶抑制剂。研究人员合成了一系列苯基-3-丁烯-2-酮衍生物 1-9,并评估了它们对人类胎盘芳香化酶的抑制活性。与标准芳香化酶抑制药物来曲唑(IC50 =0.0147 ± 1.对两种中等抑制剂 4 和 8 进行的动力学研究显示,它们分别具有竞争型和混合型抑制作用:结果:对所有活性化合物进行的 Docking 研究表明,这些化合物的结合点邻近血红素基团,并与芳香化酶的关键残基 Met374 相互作用。STD-NMR 进一步强调了这些配体与芳香化酶的相互作用:基于 STD-NMR 的表位图显示,烷基链和芳香环与受体(芳香化酶)非常接近。研究还发现,这些化合物对人类成纤维细胞(BJ 细胞)具有苯毒性。因此,本研究发现了新的芳香化酶抑制剂(化合物 4 和 8),可用于进一步的临床前和临床研究。
{"title":"Identification of Non-steroidal Aromatase Inhibitors via In silico and In vitro Studies","authors":"Humaira Zafar, Rabbia Anis, Sana Hafeez, Atia-Tul Wahab, Maria Aqeel Khan, Fatima Zehra Basha, Innokentiy Maslennikov, Muhammad Iqbal Choudhary","doi":"10.2174/1573406419666230330082426","DOIUrl":"10.2174/1573406419666230330082426","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is the most common cancer affecting women worldwide,\u0000including Pakistan. More than half of breast cancer patients have hormone-dependent breast cancer,\u0000which is developed due to the over-production of estrogen (the main hormone in breast cancer).</p><p><strong>Method: </strong>The biosynthesis of estrogen is catalyzed by the aromatase enzyme, which thus serves as a\u0000target for the treatment of breast cancer. During the current study, biochemical, computational, and\u0000STD-NMR methods were employed to identify new aromatase inhibitors. A series of phenyl-3-\u0000butene-2-one derivatives 1-9 were synthesized and evaluated for human placental aromatase inhibitory activity. Among them, four compounds 2, 3, 4, and 8 showed a moderate to weak inhibitory activity (IC50 = 22.6 - 47.9 µM), as compared to standard aromatase inhibitory drugs, letrozole (IC50 =\u00000.0147 ± 1.45 µM), anastrozole (IC50 = 0.0094 ± 0.91 µM), and exemestane (IC50 = 0.2 ± 0.032 µM).\u0000Kinetic studies on two moderate inhibitors, 4 and 8, revealed a competitive- and mixed-type of inhibition, respectively.</p><p><strong>Result: </strong>Docking studies on all active compounds indicated their binding adjacent to the heme group\u0000and interaction with Met374, a critical residue of aromatase. STD-NMR further highlighted the interactions of these ligands with the aromatase enzyme.</p><p><strong>Conclusion: </strong>STD-NMR-based epitope mapping indicated close proximity of the alkyl chain followed by an aromatic ring with the receptor (aromatase). These compounds were also found to be\u0000non-cytotoxic against human fibroblast cells (BJ cells). Thus, the current study has identified new\u0000aromatase inhibitors (compounds 4, and 8) for further pre-clinical and clinical research.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9603384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis, In silico Studies, and Anti-proliferative Assessment. 新的尼氟酸衍生物作为EGFR抑制剂:设计、合成、计算机研究和抗增殖评估。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666221219144804
Yahya S Yaseen, Ammar A Razzak Mahmood, Ali H Abbas, Wurood A Shihab, Lubna H Tahtamouni

Background: 1,3,4-oxadizole and pyrazole derivatives are very important scaffolds for medicinal chemistry. A literature survey revealed that they possess a wide spectrum of biological activities including anti-inflammatory and antitumor effects.

Objectives: To describe the synthesis and evaluation of two classes of new niflumic acid (NF) derivatives, the 1,3,4-oxadizole derivatives (compounds 3 and (4A-E) and pyrazole derivatives (compounds 5 and 6), as EGFR tyrosine kinase inhibitors in silico and in vitro.

Methods: The designed compounds were synthesized using conventional organic synthesis methods. The antitumor activities of the new NF derivatives against HepG2 hepatocellular carcinoma and A549 non-small cell lung cancer cell lines were assessed in vitro via MTT assay, flow cytometry, RT-PCR, as well as via molecular docking studies.

Results: The cytotoxicity results indicated that the newly synthesized NF derivatives were cytotoxic against the two cancer cell lines, with compound 6 being the most cytotoxic, achieving the lowest IC50 concentration. Furthermore, compound 6 targeted EGFR tyrosine kinase leading to cell cycle arrest at the G2/M cell cycle phase and induction of apoptosis. The in vitro biological investigation results matched those of the molecular docking analysis. In conclusion, the new NF derivatives, specifically compound 6, exhibited favorable pharmacokinetic features and are promising EGFR tyrosine kinase inhibitors.

Conclusion: A series of niflumic acid derivatives (3, 4A-E, 5, and 6) were successfully created, and FT-IR, 1H, 13CNMR, and HRMS were used to confirm their chemical structures. According to molecular docking studies, compounds 3, 5, and 6 have the highest docking scores (ΔG), and most tested compounds have a good pharmacokinetic profile. Results of compound 6 in vitro antitumor activities showed that it is a promising EGFR tyrosine kinase inhibitor.

背景:1,3,4-恶二唑和吡唑衍生物是非常重要的药物化学支架。文献调查显示,它们具有广泛的生物活性,包括抗炎和抗肿瘤作用。目的:描述两类新型尼氟昔酸(NF)衍生物的合成和评价,即1,3,4-恶二唑衍生物(化合物3和(4A-E))和吡唑衍生物(化合物5和6),作为EGFR酪氨酸激酶在硅中和体外的抑制剂。方法:采用常规有机合成方法合成所设计的化合物。通过MTT法、流式细胞术、RT-PCR及分子对接研究,评价了新型NF衍生物对HepG2型肝癌和A549型非小细胞肺癌细胞株的体外抗肿瘤活性。结果:细胞毒性实验结果表明,新合成的NF衍生物对两种癌细胞均具有细胞毒性,其中化合物6的细胞毒性最强,IC50浓度最低。此外,化合物6靶向EGFR酪氨酸激酶,导致细胞周期阻滞在G2/M细胞周期期并诱导凋亡。体外生物学研究结果与分子对接分析结果吻合。总之,新的NF衍生物,特别是化合物6,表现出良好的药代动力学特征,是有希望的EGFR酪氨酸激酶抑制剂。结论:成功合成了一系列尼氟酸衍生物(3、4A-E、5和6),并利用FT-IR、1H、13CNMR和HRMS对其化学结构进行了确证。根据分子对接研究,化合物3、5和6具有最高的对接分数(ΔG),并且大多数被测试的化合物具有良好的药代动力学特征。化合物6的体外抗肿瘤活性表明,它是一种很有前途的EGFR酪氨酸激酶抑制剂。
{"title":"New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis, <i>In silico</i> Studies, and Anti-proliferative Assessment.","authors":"Yahya S Yaseen,&nbsp;Ammar A Razzak Mahmood,&nbsp;Ali H Abbas,&nbsp;Wurood A Shihab,&nbsp;Lubna H Tahtamouni","doi":"10.2174/1573406419666221219144804","DOIUrl":"https://doi.org/10.2174/1573406419666221219144804","url":null,"abstract":"<p><strong>Background: </strong>1,3,4-oxadizole and pyrazole derivatives are very important scaffolds for medicinal chemistry. A literature survey revealed that they possess a wide spectrum of biological activities including anti-inflammatory and antitumor effects.</p><p><strong>Objectives: </strong>To describe the synthesis and evaluation of two classes of new niflumic acid (NF) derivatives, the 1,3,4-oxadizole derivatives (compounds 3 and (4A-E) and pyrazole derivatives (compounds 5 and 6), as EGFR tyrosine kinase inhibitors in silico and in vitro.</p><p><strong>Methods: </strong>The designed compounds were synthesized using conventional organic synthesis methods. The antitumor activities of the new NF derivatives against HepG2 hepatocellular carcinoma and A549 non-small cell lung cancer cell lines were assessed in vitro via MTT assay, flow cytometry, RT-PCR, as well as via molecular docking studies.</p><p><strong>Results: </strong>The cytotoxicity results indicated that the newly synthesized NF derivatives were cytotoxic against the two cancer cell lines, with compound 6 being the most cytotoxic, achieving the lowest IC<sub>50</sub> concentration. Furthermore, compound 6 targeted EGFR tyrosine kinase leading to cell cycle arrest at the G2/M cell cycle phase and induction of apoptosis. The in vitro biological investigation results matched those of the molecular docking analysis. In conclusion, the new NF derivatives, specifically compound 6, exhibited favorable pharmacokinetic features and are promising EGFR tyrosine kinase inhibitors.</p><p><strong>Conclusion: </strong>A series of niflumic acid derivatives (3, 4A-E, 5, and 6) were successfully created, and FT-IR, <sup>1</sub>H, <sub>13</sub>CNMR, and HRMS were used to confirm their chemical structures. According to molecular docking studies, compounds 3, 5, and 6 have the highest docking scores (ΔG), and most tested compounds have a good pharmacokinetic profile. Results of compound 6 in vitro antitumor activities showed that it is a promising EGFR tyrosine kinase inhibitor.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9818128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GPR18 and GPR55-related Ligands Serving as Antagonists or Agonists: Current Situation, Challenges and Perspectives. GPR18和gpr55相关配体作为拮抗剂或激动剂:现状、挑战和展望
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666230406095220
Linjie Zhang, Yiwen Fang, Sijing Hang, Wenhui Wu, Ruilong Sheng, Ruihua Guo

GPCR superfamily, the largest known family of membrane receptors, consists of six classes from A to F. GPR18 and GPR55, δ-branch of A class, had been reported to have no confirmed endogenous ligand and were named as "orphan receptors". Previous studies suggest that both GPR18 and GPR55 are possibly related to the migration and proliferation of cancer cells, macrophages and other inflammation-associated immune cells. Thus, they may be potential targets for inflammation, cancer and analgesia therapy. In this paper, we aimed to summarize the chemical structures and bioactivities of the agonists and antagonists of GPR18 and GPR55; moreover, we have briefly discussed the challenges and future perspectives in this field. This review will be beneficial for further design and synthesis of efficient agonists and antagonists towards GPR18 and GPR55- related disease treatment.

GPCR超家族是已知最大的膜受体家族,由A ~ f 6个类组成,为A类的δ分支GPR18和GPR55,据报道没有确定的内源性配体,被称为“孤儿受体”。既往研究表明,GPR18和GPR55都可能与癌细胞、巨噬细胞等炎症相关免疫细胞的迁移和增殖有关。因此,它们可能是炎症、癌症和镇痛治疗的潜在靶点。本文综述了GPR18和GPR55的激动剂和拮抗剂的化学结构和生物活性;此外,我们还简要讨论了该领域的挑战和未来前景。这一综述将有助于进一步设计和合成高效的GPR18和GPR55相关疾病的激动剂和拮抗剂。
{"title":"GPR18 and GPR55-related Ligands Serving as Antagonists or Agonists: Current Situation, Challenges and Perspectives.","authors":"Linjie Zhang,&nbsp;Yiwen Fang,&nbsp;Sijing Hang,&nbsp;Wenhui Wu,&nbsp;Ruilong Sheng,&nbsp;Ruihua Guo","doi":"10.2174/1573406419666230406095220","DOIUrl":"https://doi.org/10.2174/1573406419666230406095220","url":null,"abstract":"<p><p>GPCR superfamily, the largest known family of membrane receptors, consists of six classes from A to F. GPR18 and GPR55, δ-branch of A class, had been reported to have no confirmed endogenous ligand and were named as \"orphan receptors\". Previous studies suggest that both GPR18 and GPR55 are possibly related to the migration and proliferation of cancer cells, macrophages and other inflammation-associated immune cells. Thus, they may be potential targets for inflammation, cancer and analgesia therapy. In this paper, we aimed to summarize the chemical structures and bioactivities of the agonists and antagonists of GPR18 and GPR55; moreover, we have briefly discussed the challenges and future perspectives in this field. This review will be beneficial for further design and synthesis of efficient agonists and antagonists towards GPR18 and GPR55- related disease treatment.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10045558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insight on Structural Modification, Cytotoxic or Anti-Proliferative Activity, Structure-Activity Relationship of Berberine Derivatives. 小檗碱衍生物的结构修饰、细胞毒性或抗增殖活性、构效关系研究。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666230403120956
Mengxuan Yin, Jiajia Mou, Lili Sun, Yanru Deng, Xiaoliang Ren

Berberine (BBR) is a quaternary ammonium alkaloid isolated from the Traditional Chinese Medicine Coptis chinensis. It possesses a plethora of pharmacological activities because its unique structure properties make it readily interact with macromolecules through π-π stacking and electrostatic interaction. Its anti-tumor effects are receiving more and more attention in recent years. Cytotoxicity and anti-proliferation are the important anti-tumor modes of BBR, which have been studied by many research groups. This study aims to review the structural modifications of BBR and its cytotoxic derivatives. Also, to study the corresponding structure-activity relationship. BBR showed potential activities toward tumor cells, however, its modest activity and poor physicochemical properties hindered its application in clinical. Structural modification is a common and effective approach to improve BBR's cytotoxic or anti-proliferative activities. The structural modifications of BBR, the cytotoxic or anti-proliferative activities of its derivatives, and the corresponding structure-activity relationship (SAR) were summarized in the review. The concluded SAR of BBR derivatives with their cytotoxic or anti-proliferative activities will provide great prospects for the future anti-tumor drug design with BBR as the lead compound.

小檗碱(Berberine, BBR)是从中药黄连中分离得到的季铵盐类生物碱。由于其独特的结构性质使其易于通过π-π堆叠和静电相互作用与大分子相互作用,因此具有丰富的药理活性。近年来,其抗肿瘤作用越来越受到人们的关注。细胞毒性和抗增殖是BBR的重要抗肿瘤模式,已被许多研究小组研究。本研究旨在综述BBR及其细胞毒性衍生物的结构修饰。并研究相应的构效关系。BBR对肿瘤细胞具有潜在的活性,但其活性不高,理化性质较差,阻碍了其临床应用。结构修饰是提高BBR细胞毒性或抗增殖活性的一种常见而有效的方法。本文综述了BBR的结构修饰、其衍生物的细胞毒性或抗增殖活性以及相应的构效关系。研究结果表明,BBR衍生物具有细胞毒性或抗增殖活性,为未来以BBR为先导化合物的抗肿瘤药物设计提供了广阔的前景。
{"title":"Insight on Structural Modification, Cytotoxic or Anti-Proliferative Activity, Structure-Activity Relationship of Berberine Derivatives.","authors":"Mengxuan Yin,&nbsp;Jiajia Mou,&nbsp;Lili Sun,&nbsp;Yanru Deng,&nbsp;Xiaoliang Ren","doi":"10.2174/1573406419666230403120956","DOIUrl":"https://doi.org/10.2174/1573406419666230403120956","url":null,"abstract":"<p><p>Berberine (BBR) is a quaternary ammonium alkaloid isolated from the Traditional Chinese Medicine <i>Coptis chinensis</i>. It possesses a plethora of pharmacological activities because its unique structure properties make it readily interact with macromolecules through π-π stacking and electrostatic interaction. Its anti-tumor effects are receiving more and more attention in recent years. Cytotoxicity and anti-proliferation are the important anti-tumor modes of BBR, which have been studied by many research groups. This study aims to review the structural modifications of BBR and its cytotoxic derivatives. Also, to study the corresponding structure-activity relationship. BBR showed potential activities toward tumor cells, however, its modest activity and poor physicochemical properties hindered its application in clinical. Structural modification is a common and effective approach to improve BBR's cytotoxic or anti-proliferative activities. The structural modifications of BBR, the cytotoxic or anti-proliferative activities of its derivatives, and the corresponding structure-activity relationship (SAR) were summarized in the review. The concluded SAR of BBR derivatives with their cytotoxic or anti-proliferative activities will provide great prospects for the future anti-tumor drug design with BBR as the lead compound.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10046196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quinoline-based Anti-oncogenic Molecules: Synthesis and Biological Evaluation. 喹啉类抗肿瘤分子的合成及生物学评价
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666230411110025
Shivangi Sharma, Shivendra Singh, Dhananjay Yadav

Quinoline and its analogues are found in various natural products, many of which are active pharmacophores with significant bioactivities. This article discussed the plethora of quinoline derivatives and their analogues that have anti-cancer properties. The review will be helpful for the scientific community since several possible anticancer drugs based on quinolines are discussed here. In addition to this, the synthetic aspect of many such quinoline derivatives showing anti-cancer activities is also revealed in this article. These quinoline-based anti-oncogenic molecules can be synthesized using several acids, bases, and azides or with the help of reagents like Jone's reagent and Lawesson's reagent.

喹啉及其类似物存在于各种天然产物中,其中许多是具有显著生物活性的活性药效团。本文讨论了大量具有抗癌特性的喹啉衍生物及其类似物。这篇综述将对科学界有所帮助,因为本文讨论了几种基于喹啉的可能的抗癌药物。除此之外,本文还揭示了许多具有抗癌活性的喹啉衍生物的合成方面。这些以喹啉为基础的抗癌分子可以用几种酸、碱和叠氮化物合成,也可以借助于琼斯试剂和劳森试剂。
{"title":"Quinoline-based Anti-oncogenic Molecules: Synthesis and Biological Evaluation.","authors":"Shivangi Sharma,&nbsp;Shivendra Singh,&nbsp;Dhananjay Yadav","doi":"10.2174/1573406419666230411110025","DOIUrl":"https://doi.org/10.2174/1573406419666230411110025","url":null,"abstract":"<p><p>Quinoline and its analogues are found in various natural products, many of which are active pharmacophores with significant bioactivities. This article discussed the plethora of quinoline derivatives and their analogues that have anti-cancer properties. The review will be helpful for the scientific community since several possible anticancer drugs based on quinolines are discussed here. In addition to this, the synthetic aspect of many such quinoline derivatives showing anti-cancer activities is also revealed in this article. These quinoline-based anti-oncogenic molecules can be synthesized using several acids, bases, and azides or with the help of reagents like Jone's reagent and Lawesson's reagent.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10046200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Series of Trifluoromethylisoxazolyl- and Trifluoromethylpyrazolyl- Substituted (Hetero)aromatic Sulfonamide Carbonic Anhydrase Inhibitors: Synthesis, and Convenient Prioritization Workflow for Further In Vivo Studies. 一系列三氟甲基异恶唑基和三氟甲基吡唑基取代(杂)芳族磺酰胺碳酸酐酶抑制剂:合成和进一步体内研究的便捷优先排序工作流程
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406418666220831112049
Nikolina Sibinčić, Stanislav Kalinin, Vladimir Sharoyko, Julia Efimova, Olga A Gasilina, Mikhail Korsakov, Maxim Gureev, Mikhail Krasavin

Aims: To synthesize novel sulfonamide inhibitors of carbonic anhydrase and develop in vitro prioritization workflow to select compounds for in vivo evaluation.

Background: Carbonic anhydrase (CA) inhibitors gain significant attention in the context of drug discovery research for glaucoma, hypoxic malignancies, and bacterial infections. In previous works, we have successfully used direct sulfochlorination approach to develop diverse heterocyclic primary sulfonamides with remarkable activity and selectivity against therapeutically relevant CA isoforms.

Objective: Synthesis and investigation of the CA inhibitory properties of novel trifluoromethylisoxazolyl- and trifluoromethylpyrazolyl-substituted (hetero)aromatic sulfonamides.

Methods: Thirteen trifluoromethylisoxazolyl- and thirteen trifluoromethylpyrazolyl-substituted (hetero) aromatic sulfonamides were synthesized by direct sulfochlorination of hydroxyisoxazolines and pyrazoles followed by reaction with ammonia. The compound structures were confirmed by 1H and 13C NMR as well as element analysis. The obtained compounds were evaluated, using the CA esterase activity assay, for their potential to block the catalytic activity of bovine CA (bCA).

Results: Eight most potent compounds selected based on the esterase activity assay data were tested for direct affinity to the enzyme using the thermal shift assay (TSA). These compounds displayed Kd values (measured by TSA) in the double-digit nanomolar range, thus showing comparable activity to the reference drug acetazolamide.

Conclusion: Coupling the bCA esterase activity assay with thermal shift assay represents a streamlined and economical strategy for the prioritization of sulfonamide CA inhibitors for subsequent evaluation in vivo.

目的:合成新型磺胺类碳酸酐酶抑制剂,并建立体外筛选流程,筛选化合物进行体内评价。背景:碳酸酐酶(CA)抑制剂在青光眼、缺氧恶性肿瘤和细菌感染的药物发现研究中受到了极大的关注。在以前的工作中,我们已经成功地使用直接磺化氯化方法开发了多种杂环伯胺类药物,这些药物对治疗相关的CA异构体具有显著的活性和选择性。目的:合成并研究新型三氟甲基异恶唑和三氟甲基吡唑取代(杂)芳砜胺的CA抑制性能。方法:以羟基异恶唑和吡唑为原料,采用直接磺化氯化法合成13种三氟甲基异恶唑和13种三氟甲基吡唑取代(杂)芳砜酰胺。化合物结构经1H、13C核磁共振及元素分析证实。使用CA酯酶活性测定法对所得化合物进行了评价,以确定它们具有阻断牛CA (bCA)催化活性的潜力。结果:根据酯酶活性测定数据选择的8种最有效的化合物使用热移试验(TSA)测试了与酶的直接亲和力。这些化合物的Kd值(通过TSA测量)在两位数纳摩尔范围内,因此显示出与参比药物乙酰唑胺相当的活性。结论:将bCA酯酶活性测定与热移测定相结合是一种简化和经济的策略,可以优先考虑磺胺类CA抑制剂,以便随后在体内进行评估。
{"title":"A Series of Trifluoromethylisoxazolyl- and Trifluoromethylpyrazolyl- Substituted (Hetero)aromatic Sulfonamide Carbonic Anhydrase Inhibitors: Synthesis, and Convenient Prioritization Workflow for Further <i>In Vivo</i> Studies.","authors":"Nikolina Sibinčić,&nbsp;Stanislav Kalinin,&nbsp;Vladimir Sharoyko,&nbsp;Julia Efimova,&nbsp;Olga A Gasilina,&nbsp;Mikhail Korsakov,&nbsp;Maxim Gureev,&nbsp;Mikhail Krasavin","doi":"10.2174/1573406418666220831112049","DOIUrl":"https://doi.org/10.2174/1573406418666220831112049","url":null,"abstract":"<p><strong>Aims: </strong>To synthesize novel sulfonamide inhibitors of carbonic anhydrase and develop in vitro prioritization workflow to select compounds for in vivo evaluation.</p><p><strong>Background: </strong>Carbonic anhydrase (CA) inhibitors gain significant attention in the context of drug discovery research for glaucoma, hypoxic malignancies, and bacterial infections. In previous works, we have successfully used direct sulfochlorination approach to develop diverse heterocyclic primary sulfonamides with remarkable activity and selectivity against therapeutically relevant CA isoforms.</p><p><strong>Objective: </strong>Synthesis and investigation of the CA inhibitory properties of novel trifluoromethylisoxazolyl- and trifluoromethylpyrazolyl-substituted (hetero)aromatic sulfonamides.</p><p><strong>Methods: </strong>Thirteen trifluoromethylisoxazolyl- and thirteen trifluoromethylpyrazolyl-substituted (hetero) aromatic sulfonamides were synthesized by direct sulfochlorination of hydroxyisoxazolines and pyrazoles followed by reaction with ammonia. The compound structures were confirmed by <sup>1</sup>H and <sup>13</sup>C NMR as well as element analysis. The obtained compounds were evaluated, using the CA esterase activity assay, for their potential to block the catalytic activity of bovine CA (bCA).</p><p><strong>Results: </strong>Eight most potent compounds selected based on the esterase activity assay data were tested for direct affinity to the enzyme using the thermal shift assay (TSA). These compounds displayed Kd values (measured by TSA) in the double-digit nanomolar range, thus showing comparable activity to the reference drug acetazolamide.</p><p><strong>Conclusion: </strong>Coupling the bCA esterase activity assay with thermal shift assay represents a streamlined and economical strategy for the prioritization of sulfonamide CA inhibitors for subsequent evaluation in vivo.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9076202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
In vitro and In silico Xanthine Oxidase Inhibitory Activities of 3-Aryl-2- thioxo-2,3-dihydroquinazolin-4(1H)-one Derivatives. 3-芳基-2-硫氧基-2,3-二氢喹唑啉-4(1H)- 1衍生物的体外和体内黄嘌呤氧化酶抑制活性。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406418666220620124034
Afshan Gul, Syed Muhammad Saad, Humaira Zafar, Atia-Tul-Wahab, Khalid Mohammed Khan, M Iqbal Choudhary

Background: Hyperuricemia is associated with several disease conditions, such as atherosclerosis, arthritis, kidney stones, and many others. Xanthine oxidase (XO) is an enzyme that catalyzes the conversion of xanthine to uric acid. Hence, XO is a major therapeutic drug target in the treatment of hyperuricemia and associated disorders.

Objectives: The current study aimed to identify XO inhibitors based on quinazoline derivatives, with the potential to be used against gout and other hyperuricemia-associated diseases.

Methods: In the current study, eighteen quinazoline derivatives 2-19 were synthesized and assessed for their in vitro xanthine Oxidase (XO) inhibitory activity. Furthermore, the most active compounds, 5 and 17, were subjected to kinetics studies, followed by computational docking. Human BJ fibroblast cells were used to measure the cytotoxicity of active compounds.

Results: Compounds 4-6, 8, 10, 13, 15-17, and 19 were found active against XO, with an IC50 values between 33.688 to 362.173μM. The obtained results showed that compounds 5 and 17 possess a significant xanthine oxidase inhibitory activity. The kinetics and molecular docking studies suggested that compounds 5 (IC50 = 39.904 ± 0.21 μM) and 17 (IC50 = 33.688 ± 0.30 μM) bind in the allosteric site of XO and exhibit a non-competitive type of inhibition. The molecular docking studies also predicted that the NH group of the pyrimidine ring binds with Ser344 residues of XO. Furthermore, all active compounds were non-cytotoxic on the human BJ fibroblasts cell line.

Conclusion: This study identifies a series of quinazoline compounds as xanthine oxidase inhibitors, with the potential to be further investigated.

背景:高尿酸血症与几种疾病有关,如动脉粥样硬化、关节炎、肾结石和许多其他疾病。黄嘌呤氧化酶(XO)是一种催化黄嘌呤转化为尿酸的酶。因此,XO是治疗高尿酸血症及相关疾病的主要治疗药物靶点。目的:目前的研究旨在鉴定基于喹唑啉衍生物的XO抑制剂,具有用于治疗痛风和其他高尿酸血症相关疾病的潜力。方法:合成了18种喹唑啉衍生物2-19,并对其黄嘌呤氧化酶(xanthine Oxidase, XO)体外抑制活性进行了评价。此外,最活跃的化合物5和17进行了动力学研究,然后进行了计算对接。用人BJ成纤维细胞测定活性化合物的细胞毒性。结果:化合物4 ~ 6、8、10、13、15 ~ 17、19对XO有活性,IC50值在33.688 ~ 362.173μM之间。结果表明,化合物5和17具有明显的黄嘌呤氧化酶抑制活性。动力学和分子对接研究表明,化合物5 (IC50 = 39.904±0.21 μM)和17 (IC50 = 33.688±0.30 μM)结合在XO的变构位点,表现出非竞争性抑制。分子对接研究也预测了嘧啶环的NH基团与XO的Ser344残基结合。此外,所有活性化合物对人BJ成纤维细胞系均无细胞毒性。结论:本研究鉴定了一系列喹唑啉类化合物作为黄嘌呤氧化酶抑制剂,具有进一步研究的潜力。
{"title":"<i>In vitro</i> and <i>In silico</i> Xanthine Oxidase Inhibitory Activities of 3-Aryl-2- thioxo-2,3-dihydroquinazolin-4(1H)-one Derivatives.","authors":"Afshan Gul,&nbsp;Syed Muhammad Saad,&nbsp;Humaira Zafar,&nbsp;Atia-Tul-Wahab,&nbsp;Khalid Mohammed Khan,&nbsp;M Iqbal Choudhary","doi":"10.2174/1573406418666220620124034","DOIUrl":"https://doi.org/10.2174/1573406418666220620124034","url":null,"abstract":"<p><strong>Background: </strong>Hyperuricemia is associated with several disease conditions, such as atherosclerosis, arthritis, kidney stones, and many others. Xanthine oxidase (XO) is an enzyme that catalyzes the conversion of xanthine to uric acid. Hence, XO is a major therapeutic drug target in the treatment of hyperuricemia and associated disorders.</p><p><strong>Objectives: </strong>The current study aimed to identify XO inhibitors based on quinazoline derivatives, with the potential to be used against gout and other hyperuricemia-associated diseases.</p><p><strong>Methods: </strong>In the current study, eighteen quinazoline derivatives 2-19 were synthesized and assessed for their in vitro xanthine Oxidase (XO) inhibitory activity. Furthermore, the most active compounds, 5 and 17, were subjected to kinetics studies, followed by computational docking. Human BJ fibroblast cells were used to measure the cytotoxicity of active compounds.</p><p><strong>Results: </strong>Compounds 4-6, 8, 10, 13, 15-17, and 19 were found active against XO, with an IC<sub>50</sub> values between 33.688 to 362.173μM. The obtained results showed that compounds 5 and 17 possess a significant xanthine oxidase inhibitory activity. The kinetics and molecular docking studies suggested that compounds 5 (IC<sub>50</sub> = 39.904 ± 0.21 μM) and 17 (IC<sub>50</sub> = 33.688 ± 0.30 μM) bind in the allosteric site of XO and exhibit a non-competitive type of inhibition. The molecular docking studies also predicted that the NH group of the pyrimidine ring binds with Ser344 residues of XO. Furthermore, all active compounds were non-cytotoxic on the human BJ fibroblasts cell line.</p><p><strong>Conclusion: </strong>This study identifies a series of quinazoline compounds as xanthine oxidase inhibitors, with the potential to be further investigated.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9173447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, Biological Evaluation, and Docking Studies of Open-Chain Carbohydrate Amides as Acetylcholinesterase Inhibitors. 开链碳水化合物酰胺类乙酰胆碱酯酶抑制剂的合成、生物学评价及对接研究。
IF 2.3 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1573406419666221202154219
Rita Gonçalves-Pereira, Jose A Figueiredo, Susana D Lucas, Maria I García-Moreno, Carmen O Mellet, Amelia P Rauter, Maria I Ismael

Introduction: Alzheimer's disease is a multifactorial syndrome, which is not yet fully understood, causing memory loss, dementia, and, ultimately, death. Acetylcholinesterase inhibitors are the mainstay drugs that are used in disease-symptomatic treatment. In this work, we report a new synthetic route yielding sugar amides as low to moderate acetylcholinesterase inhibitors.

Methods: Commercially available diacetone glucose was converted into perbenzyl D-glucono-1,4- lactone, which reacted with aromatic or aliphatic amines to afford the corresponding new amides in a high isolated yield. Docking studies of the most promising hydroxybutylamide and benzylamide were performed to assign binding interactions with acetylcholinesterase and determine the key features for bioactivity.

Results: The inhibitors are accommodated in enzyme gorge, blocking the access to Ser203 mainly due to π-π stacking interactions of sugar benzyl groups with the aromatic gorge residues, Tyr337 and Tyr341 for both inhibitors and Trp439 only for the hydroxybutylamide.

Conclusion: Bonding is also significant through sugar interaction with the residues Tyr124 and Ser125-OH in both inhibitors. Flexibility of these open-chain structures seems to be quite relevant for the observed binding to acetylcholinesterase.

简介:阿尔茨海默病是一种多因素综合征,尚未完全了解,导致记忆丧失,痴呆,并最终死亡。乙酰胆碱酯酶抑制剂是用于疾病症状治疗的主要药物。在这项工作中,我们报告了一种新的合成路线,生产糖酰胺作为低至中等乙酰胆碱酯酶抑制剂。方法:将市售的二丙酮葡萄糖转化为过苄基d -葡萄糖-1,4-内酯,与芳香胺或脂肪胺反应,以高分离收率得到相应的新酰胺。对最有前途的羟丁酰胺和苄酰胺进行对接研究,以确定其与乙酰胆碱酯酶的结合相互作用,并确定其生物活性的关键特征。结果:抑制剂被调节在酶峡谷中,阻断Ser203的通路主要是由于糖苄基与芳香峡谷残基的π-π堆叠相互作用,抑制剂均适用于Tyr337和Tyr341,而Trp439仅适用于羟丁酰胺。结论:在这两种抑制剂中,糖与Tyr124和Ser125-OH残基的相互作用也很重要。这些开链结构的柔韧性似乎与观察到的与乙酰胆碱酯酶的结合密切相关。
{"title":"Synthesis, Biological Evaluation, and Docking Studies of Open-Chain Carbohydrate Amides as Acetylcholinesterase Inhibitors.","authors":"Rita Gonçalves-Pereira,&nbsp;Jose A Figueiredo,&nbsp;Susana D Lucas,&nbsp;Maria I García-Moreno,&nbsp;Carmen O Mellet,&nbsp;Amelia P Rauter,&nbsp;Maria I Ismael","doi":"10.2174/1573406419666221202154219","DOIUrl":"https://doi.org/10.2174/1573406419666221202154219","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's disease is a multifactorial syndrome, which is not yet fully understood, causing memory loss, dementia, and, ultimately, death. Acetylcholinesterase inhibitors are the mainstay drugs that are used in disease-symptomatic treatment. In this work, we report a new synthetic route yielding sugar amides as low to moderate acetylcholinesterase inhibitors.</p><p><strong>Methods: </strong>Commercially available diacetone glucose was converted into perbenzyl D-glucono-1,4- lactone, which reacted with aromatic or aliphatic amines to afford the corresponding new amides in a high isolated yield. Docking studies of the most promising hydroxybutylamide and benzylamide were performed to assign binding interactions with acetylcholinesterase and determine the key features for bioactivity.</p><p><strong>Results: </strong>The inhibitors are accommodated in enzyme gorge, blocking the access to Ser203 mainly due to π-π stacking interactions of sugar benzyl groups with the aromatic gorge residues, Tyr337 and Tyr341 for both inhibitors and Trp439 only for the hydroxybutylamide.</p><p><strong>Conclusion: </strong>Bonding is also significant through sugar interaction with the residues Tyr124 and Ser125-OH in both inhibitors. Flexibility of these open-chain structures seems to be quite relevant for the observed binding to acetylcholinesterase.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9457515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1